Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InMed Pharmaceuticals (INM) Total Liabilities: 2022-2025

Historic Total Liabilities for InMed Pharmaceuticals (INM) over the last 4 years, with Jun 2025 value amounting to $2.1 million.

  • InMed Pharmaceuticals' Total Liabilities fell 14.46% to $1.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.8 million, marking a year-over-year decrease of 14.46%. This contributed to the annual value of $2.1 million for FY2025, which is 18.00% down from last year.
  • Latest data reveals that InMed Pharmaceuticals reported Total Liabilities of $2.1 million as of FY2025, which was down 18.00% from $2.6 million recorded in FY2024.
  • InMed Pharmaceuticals' 5-year Total Liabilities high stood at $3.7 million for FY2022, and its period low was $2.0 million during FY2023.
  • Its 3-year average for Total Liabilities is $2.3 million, with a median of $2.1 million in 2025.
  • As far as peak fluctuations go, InMed Pharmaceuticals' Total Liabilities crashed by 45.63% in 2023, and later increased by 29.76% in 2024.
  • InMed Pharmaceuticals' Total Liabilities (Yearly) stood at $3.7 million in 2022, then plummeted by 45.63% to $2.0 million in 2023, then grew by 29.76% to $2.6 million in 2024, then fell by 18.00% to $2.1 million in 2025.